Office of the Commissioner of Lobbying of Canada Office of the Commissioner of Lobbying of Canada

Language selection

Registry of Lobbyists

Advanced Registry Search Results

Search History (1)

Search Criteria

  1. Client, organization or corporation number: 5088
Share this search Create an alert
Start over
Modify criteria

Refine registrations results by

If you would like to view a summary of the last 12 months for a lobbying activity, use the 12-Month Lobbying Activity Search

Monthly communication reports (278)
Results: 1-50 | Export
  1. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-04-30
    Posted: 2024-05-15
    Designated public office holders:
    • Rodrigo Arancibia, Director, Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
    • Health
      •
  2. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-04-16
    Posted: 2024-05-15
    Designated public office holders:
    • Laurel Chester, Senior Advisor | Innovation, Science and Economic Development Canada (ISED)
    • Jaxson Khan, Sr Policy Advisor, MINISTER OF INNOVATION, SCIENCE AND INDUSTRY | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
    • Government Procurement
    • Health
      •
  3. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-04-16
    Posted: 2024-05-15
    Designated public office holders:
    • Colin Deacon, Senator | Senate of Canada
    Subject matters:
    • Economic Development
      •
  4. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-04-16
    Posted: 2024-05-15
    Designated public office holders:
    • Semhar Zerat, Director, Programs and Partnerships Division | Public Health Agency of Canada (PHAC)
    Subject matters:
    • Health
      •
  5. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-04-15
    Posted: 2024-05-15
    Designated public office holders:
    • Andrea Johnston, Assistant deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Etienne-Rene Massie, Assistant Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    • Francis Bilodeau, Associate Deputy Minister, Office of the Associate Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Research and Development
    • Economic Development
    • Health
      •
  6. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-04-15
    Posted: 2024-05-15
    Designated public office holders:
    • Mark Schaan, Senior Assistant Deputy Minister, Strategy and Innovation Policy Sector - Assistant Deputy Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
    • Research and Development
    • Health
      •
  7. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-04-04
    Posted: 2024-05-15
    Designated public office holders:
    • Joel Denis, Director General, Centre for Vaccine and Therapeutics Readiness | Public Health Agency of Canada (PHAC)
    Subject matters:
    • Health
      •
  8. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-03-15
    Posted: 2024-04-15
    Designated public office holders:
    • Anita Anand, President of the Treasury Board, President's Office | Treasury Board Of Canada Secretariat (TBS)
    Subject matters:
    • Budget
    • Health
      •
  9. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-02-13
    Posted: 2024-03-15
    Designated public office holders:
    • Eshan Naik, Director of Policy, Minister's office | Health Canada (HC)
    • Ophelia John, Policy Advisor, Office of the Minister of Health | Health Canada (HC)
    Subject matters:
    • Health
      •
  10. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-02-13
    Posted: 2024-03-15
    Designated public office holders:
    • Matthew Trnkus, Senior Advisor, Minister's Office | Global Affairs Canada (GAC)
    • Qasir Hanif, Director of Stakeholder Relations, Minister's Office | Global Affairs Canada (GAC)
    • Aram Shoujounian, Policy Advisor, Minister's Office | Global Affairs Canada (GAC)
    Subject matters:
    • Health
      •
  11. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-01-26
    Posted: 2024-02-15
    Designated public office holders:
    • Paul Moen, Chief of Staff | Employment and Social Development Canada (ESDC)
    • Lhori Webster, Director of Policy | Employment and Social Development Canada (ESDC)
    Subject matters:
    • Health
      •
  12. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-01-22
    Posted: 2024-02-15
    Designated public office holders:
    • Jocelyn Milburn, Director, Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
      •
  13. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-01-16
    Posted: 2024-02-15
    Designated public office holders:
    • Victor Kandasamy, Policy Advisor | Public Services and Procurement Canada (PSPC)
    Subject matters:
    • Government Procurement
      •
  14. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2024-01-09
    Posted: 2024-02-15
    Designated public office holders:
    • Ophelia John, Policy Advisor, Minister's Office | Health Canada (HC)
    Subject matters:
    • Health
    • Government Procurement
      •
  15. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-12-14
    Posted: 2024-01-15
    Designated public office holders:
    • Laurel Chester, Policy Advisor, Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
      •
  16. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-12-13
    Posted: 2024-01-15
    Designated public office holders:
    • Jocelyn Milburn, Director, Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
      •
  17. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-12-12
    Posted: 2024-01-15
    Designated public office holders:
    • Jennifer Miller, Assistant Secretary to the Cabinet | Privy Council Office (PCO)
    Subject matters:
    • Economic Development
    • Health
      •
  18. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-12-12
    Posted: 2024-01-15
    Designated public office holders:
    • Stephen Lucas, Deputy Minister | Health Canada (HC)
    Subject matters:
    • Health
      •
  19. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-12-12
    Posted: 2024-01-15
    Designated public office holders:
    • Joel Denis, Director General | Public Health Agency of Canada (PHAC)
    • Heather Jeffrey, President | Public Health Agency of Canada (PHAC)
    • Cindy Evans, Vice President, Emergency Management Branch | Public Health Agency of Canada (PHAC)
    • Erin Schock, Director, Medical Countermeasures Program | Public Health Agency of Canada (PHAC)
    Subject matters:
    • Health
    • Government Procurement
      •
  20. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-12-12
    Posted: 2024-01-15
    Designated public office holders:
    • Suzy McDonald, Associate Deputy Minister | Finance Canada (FIN)
    Subject matters:
    • Health
    • Budget
    • Economic Development
      •
  21. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-12-12
    Posted: 2024-01-15
    Designated public office holders:
    • Jocelyn Milburn, Director, Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee, Assistant Deputy Minister, Director General's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Health
    • Economic Development
      •
  22. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-12-12
    Posted: 2024-01-15
    Designated public office holders:
    • Eshan Naik, Director of Policy, Office of the Leader of the Government in the House of Commons | House of Commons
    • Jean-Sebastien Bock, Deputy Chief of Staff and Director of Policy, Office of the Minister of Health | Health Canada (HC)
    Subject matters:
    • Health
      •
  23. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-12-04
    Posted: 2024-01-15
    Designated public office holders:
    • Daniel MacDonald, Director General, Drugs for Rare Diseases, Strategic Policy Branch | Health Canada (HC)
    Subject matters:
    • Health
      •
  24. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-11-28
    Posted: 2023-12-15
    Designated public office holders:
    • Victor Kandasamy, Policy Advisor | Public Services and Procurement Canada (PSPC)
    • Mary-Rose Brown, Director of Policy | Public Services and Procurement Canada (PSPC)
    Subject matters:
    • Government Procurement
      •
  25. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-11-22
    Posted: 2023-12-15
    Designated public office holders:
    • Milan Patel, Director, Vaccine Supply & Assurance | Public Health Agency of Canada (PHAC)
    • Joel Denis, Director General, Centre for Vaccine and Therapeutic Readiness | Public Health Agency of Canada (PHAC)
    Subject matters:
    • Health
    • Government Procurement
      •
  26. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-11-08
    Posted: 2023-12-15
    Designated public office holders:
    • Mohamed-Iqbal Ravalia, Senator | Senate of Canada
    Subject matters:
    • Health
      •
  27. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-11-06
    Posted: 2023-12-15
    Designated public office holders:
    • Francesco Sorbara, Member of Parliment | House of Commons
    Subject matters:
    • Economic Development
    • Health
      •
  28. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-11-01
    Posted: 2023-12-15
    Designated public office holders:
    • Rodrigo Arancibia, Director, Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
      •
  29. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-10-25
    Posted: 2023-11-15
    Designated public office holders:
    • Ophelia John, Policy Advisor, Office of the Minister of Health | Health Canada (HC)
    Subject matters:
    • Health
      •
  30. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-10-25
    Posted: 2023-11-15
    Designated public office holders:
    • Rodrigo Arancibia, Director, Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
      •
  31. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-10-20
    Posted: 2023-11-15
    Designated public office holders:
    • Brendan Hanley, Member of Parliament | House of Commons
    Subject matters:
    • Health
      •
  32. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-10-17
    Posted: 2023-11-15
    Designated public office holders:
    • Ekateryna Nova, Policy Advisor, Seniors, Minister's Office | Employment and Social Development Canada (ESDC)
    Subject matters:
    • Health
      •
  33. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-09-29
    Posted: 2023-10-16
    Designated public office holders:
    • Rodrigo Arancibia, Director, Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
      •
  34. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-09-20
    Posted: 2023-10-16
    Designated public office holders:
    • Rodrigo Arancibia, Director, Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    • Joel Denis, Director General, Vaccine Supply and Assurance | Public Health Agency of Canada (PHAC)
    • Darryl Patterson, Director General, Biomanufacturing Strategy Implementation Team | Innovation, Science and Economic Development Canada (ISED)
    • Kasondra White, Director, Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
    • Simon Kennedy, Deputy Minister | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
    • Health
      •
  35. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-09-19
    Posted: 2023-10-16
    Designated public office holders:
    • Marie-France Proulx, Director of Communications, Minister's Office | Public Services and Procurement Canada (PSPC)
    Subject matters:
    • Economic Development
    • Health
      •
  36. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-09-13
    Posted: 2023-10-16
    Designated public office holders:
    • Rodrigo Arancibia, Director, Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Health
    • Economic Development
      •
  37. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-09-11
    Posted: 2023-10-16
    Designated public office holders:
    • Jed Graham, Policy Advisor | Health Canada (HC)
    • Eshan Naik, Director of Policy, Minister's Office | Health Canada (HC)
    Subject matters:
    • Health
      •
  38. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-08-25
    Posted: 2023-09-15
    Designated public office holders:
    • Jocelyn Milburn, Director, Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Health
    • Economic Development
      •
  39. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-08-24
    Posted: 2023-09-15
    Designated public office holders:
    • Celine Menard, Director General, Financial Analysis and Oversight Branch | Innovation, Science and Economic Development Canada (ISED)
    • Jocelyn Milburn, Director, Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
    • Eric Bourbonnais, Director, Investment Opportunities, Strategic Innovation Fund | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
    • Health
      •
  40. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-07-31
    Posted: 2023-08-15
    Designated public office holders:
    • Rodrigo Arancibia, Director, Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Health
    • Economic Development
      •
  41. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-07-13
    Posted: 2023-08-15
    Designated public office holders:
    • Jean-Yves Duclos, Minister of Health | Health Canada (HC)
    • Sandenga Yeba, Senior Policy Advisor, Minister's Office | Health Canada (HC)
    • Jamie Kippen, Chief of Staff | Health Canada (HC)
    Subject matters:
    • Economic Development
    • Health
    • Government Procurement
      •
  42. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-06-26
    Posted: 2023-07-15
    Designated public office holders:
    • Rodrigo Arancibia, Director, Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
      •
  43. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-06-06
    Posted: 2023-07-15
    Designated public office holders:
    • Darryl Patterson, Director General, Biomanufacturing Strategy Implementation Team | Innovation, Science and Economic Development Canada (ISED)
    • Andy Fillmore, Member of Parliament | House of Commons
    • Ritu Banerjee, Assistant Deputy Minister, Office of Life Sciences and Biomanufacturing Readiness | Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia, Director, Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
    • Health
      •
  44. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-05-10
    Posted: 2023-05-10
    Designated public office holders:
    • Yash Nanda, Policy Advisor, Minister's Office | Finance Canada (FIN)
    Subject matters:
    • Health
      •
  45. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-05-01
    Posted: 2023-06-15
    Designated public office holders:
    • Rodrigo Arancibia, Director, Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Health
    • Economic Development
      •
  46. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-04-27
    Posted: 2023-05-15
    Designated public office holders:
    • Jed Graham, Policy advisor, Minister's Office | Health Canada (HC)
    • Sandenga Yeba, Senior Policy Advisor, Minister's Office | Health Canada (HC)
    Subject matters:
    • Health
      •
  47. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-04-27
    Posted: 2023-05-15
    Designated public office holders:
    • Bianca Hossain, Senior Special Assistant, Minister's Office | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
    • Health
      •
  48. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-04-25
    Posted: 2023-04-26
    Designated public office holders:
    • Jo Voisin, Assistant Deputy Minister, Strategic Policy Branch | Health Canada (HC)
    Subject matters:
    • Health
      •
  49. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-04-25
    Posted: 2023-04-26
    Designated public office holders:
    • Ed Morgan, Director General, Policy, Planning and International | Health Canada (HC)
    Subject matters:
    • Health
      •
  50. GlaxoSmithKline
    Type: In-house Corporation
    Occurred: 2023-03-31
    Posted: 2023-04-03
    Designated public office holders:
    • Rodrigo Arancibia, Director, Life Science Industries Directorate | Innovation, Science and Economic Development Canada (ISED)
    Subject matters:
    • Economic Development
      •
Date Modified: